What's in a Label? Radioimmunotherapy for metastatic prostate cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23926229.
- Also identified by DOI 10.1158/1078-0432.CCR-13-1540.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prostate cancer has a highly tumor-restricted prostate-specific membrane antigen (PSMA) and may be the ideal solid-organ malignancy for treatment with radioimmunotherapy. Encouraging results using lutetium-177-labeled anti-PSMA monoclonal antibody J591 from a phase II study by Tawaga and colleagues support the continued clinical and preclinical development of radioimmunotherapy for solid tumors.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Agents
- Prostatic Neoplasms
- Radioimmunotherapy